Results: There were 832 636 live births during the study period. Exposure to corticosteroids during the first trimester occurred in 51 973 of the pregnancies. A total of 1232 isolated orofacial clefts (i.e., cleft lip, cleft palate, or cleft lip and cleft palate) were diagnosed within the first year of life, including 84 instances in which the infant had been exposed to corticosteroids during the first trimester of pregnancy. We did not identify any statistically significant increased risk of orofacial clefts associated with the use of corticosteroids: cleft lip with or without cleft palate, prevalence odds ratio (OR) 1.05 (95% confidence interval [CI] 0.80-1.38]; cleft palate alone, prevalence OR 1.23 (95% CI 0.83-1.82). Odds ratios for risk of orofacial clefts by method of delivery (i.e., oral, inhalant, nasal spray, or dermatologic and other topicals) were consistent with the overall results of the study and did not display significant heterogeneity, although the OR for cleft lip with or without cleft palate associated with the use of dermatologic corticosteroids was 1.45 (95% CI 1.03-2.05).
Interpretation:
Our results add to the safety information on a class of drugs commonly used during pregnancy. Our study did not show an increased risk of orofacial clefts with the use of corticosteroids during pregnancy. Indepth investigation of the pattern of association between orofacial clefts and the use of dermatologic corticosteroids during pregnancy indicated that this result did not signify a causal connection and likely arose from multiple statistical comparisons.
Using the information in the medical birth registry, we constructed a cohort of all live births in Denmark from Jan. 1, 1996 , to Sept. 30, 2008 . The date on which each pregnancy began was estimated by subtracting the estimated gestational age from the date of birth. Births with missing gestational age (7371 births [0.9%]) were excluded, and the final cohort included 832 636 births.
Use of corticosteroids during pregnancy
Information on all corticosteroid prescriptions given to women in the cohort and filled during the period starting four weeks before pregnancy and ending at birth was obtained from the Danish Prescription Drug Register. This register contains information on all prescriptions filled at Danish pharmacies, the only places in Denmark where prescription drugs can legally be purchased, since 1995. Each record is indexed using the recipient's personal identification number and includes the date on which the prescription was filled, the Anatomic Therapeutic Chemical (ATC) code of the drug (available from www .whocc .no /atc _ddd _index/), the number of packages dispensed, the size of the package dispensed and the number of daily defined doses in the prescription. For the purposes of our study, the date on which the prescription was filled was considered the date of use. We included corticosteroid drugs with the following ATC codes in the study : A01AC,  A07EA, C05AA, D07, D10AA, G01B, H02A,  H02B, M01BA, N02CB, R01AD, R03BA,  S01BA, S01BB, S01CA, S01CB , S02B, S02C, S03B and S03C. We grouped corticosteroid drugs according to the route of administration (oral, inhalant, nasal spray, and dermatologic and other topicals).
Orofacial clefts and other diagnostic information
Infants with orofacial clefts (clefts) were identified through the National Hospital Discharge Register. 13 This registry was established in 1977 and contains information on hospital contacts indexed by the personal identification number. The registry includes information on the dates of admission and discharge as well as the diagnoses at discharge. We had access to data for the period covering Jan. 1, 1996, to Mar. 31, 2009 . The 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) was used to code diagnostic information. Clefts were subcategorized as cleft lip with or without cleft palate (ICD-10 codes Q36 and Q37) and cleft palate alone (ICD-10 code Q35). Only diagnoses made during the first year of life were included.
Clefts were further characterized as isolated or as one of multiple birth defects (any diagnosis of a birth defect other than clefts, ICD-10 codes Q00-Q89, during the first year of life) using information from the discharge registry. Orofacial clefts in isolation were used as the main outcome measure.
We excluded children with chromosomal abnormalities (ICD-10 codes Q90-Q99) diagnosed during the first year of life from the cohort.
Potential confounders
We included information on many potential confounders. These confounders were selected using previously described associations with clefts found in the literature. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Information on maternal age at the start of pregnancy, parity and smoking status during pregnancy was obtained from the Danish Medical Birth Registry; the mother's place of origin and her place of residence at the start of pregnancy were obtained from the Danish Central Person Register, which contains complete and continually updated demographic information on all Danish residents; 24 the level of education and socioeconomic status of the mother during the year in which pregnancy started was obtained from Statistics Denmark.
Information on the following maternal morbidities was obtained from the discharge registry: infections during the first trimester (ICD-10 codes A00-B99), infections of the genito urinary tract during the first trimester (ICD-10 code O23), diabetes (ICD-10 codes O24 and E10-E14) and epilepsy (ICD-10 codes G40 and G41).
Information on the use of the following additional drugs during the first trimester was obtained from the Danish Prescription Drug Register: antiepileptic medications (ATC code N03), benzodiazepines (ATC code N05BA), β-blockers (ATC code C07A), oral contraceptives (ATC code G03A) and analgesic agents (ATC code N02).
The history of birth defects among siblings dating from the end of the study period back to 1977 was obtained from the discharge registry.
Finally, the year in which pregnancy began was also included in our analysis.
Statistical analysis
We used logistic regression analysis (SAS procedure PROC GENMOD) to estimate prevalence odds ratios (ORs) with 95% confidence intervals (CIs) to compare the prevalence odds of clefts among births with and without exposure to corticosteroids during pregnancy. In our main analysis, we estimated the effects of using corticosteroids during the first trimester (defined as the first 12
Research weeks after the start of pregnancy), the period including primary organogenesis during which exposure is most likely to cause structural defects.
Covariables that were potential confounders were included in the regression models if they were significant (likelihood ratio test p < 0.05) risk factors for clefts in univariable analyses. In univariable analyses, p values were estimated with missing values excluded. The covariables were evaluated separately for cleft lip with or without cleft palate and cleft palate alone, yielding two sets of variables included in all further regression models of the two outcomes. Since the proportions of missing values were all less than 5%, we used mode imputation for missing values in adjusted models.
Results
A total of 832 636 live births with known gestational age and no chromosomal abnormalities were included in the study cohort. Of these, 798 003 (95.8%) were singleton births and 34 633 (4.2%) were multiple births.
We identified 1232 isolated orofacial clefts diagnosed during the first year of life (305 cleft lips, 570 cleft lips with cleft palates and 357 cleft palates alone). The corresponding rates of isolated clefts diagnosed during the first year of life were 1.48, 1.05 and 0.43 per 1000 births.
In our cohort, 163 494 women (19.6%) used corticosteroids at least once during the period from four weeks before pregnancy to birth. Use of corticosteroids during the first trimester occurred among 51 973 women (6.2%). During this period, dermatologic corticosteroids were the most common form of the drug used (43.3%), followed by other topical forms (23.3%), nasal sprays (21.6%), inhalants (14.3%) and drugs taken orally (4.2%). Table 1 shows the pattern of corticosteroid use according to the potential confounders that we assessed.
To identify potential confounders for the association between corticosteroid use and risk of orofacial clefts, we first evaluated the univariable associations between the covariables identified as potential confounders and cleft lip with or without cleft palate and cleft palate alone. Table 2 shows the statistically significant (likelihood ratio test p < 0.05) risk factors for clefts from the univariable analyses.
Women who used any corticosteroid during the first trimester were not significantly more likely to bear offspring with a cleft lip with or without a cleft palate (crude OR 1.05 [95% CI 0.80-1.37]) or a cleft palate alone (crude OR 1.23 [95% CI 0.83-1.82]) than women who did not use any corticosteroid during the first trimester. Table 3 shows the adjusted ORs for the association between corticosteroid use during the first trimester of pregnancy and clefts. Testing the homogeneity of effects between any use and all possible forms of use yielded a likelihood ratio p value of 0.3174 for cleft lip with or without cleft palate and a likelihood ratio p value of 0.8907 for cleft palate alone. However, the use of dermatologic corticosteroids was associated with an increased risk of cleft lip with or without cleft palate (OR 1.45 [95% CI 1.03-2.05]). Corticosteroids in the form of inhalants, nasal sprays and other topicals were not associated with an increased risk of clefts. None of the infants with clefts had been exposed to oral corticosteroids during the first trimester. Table 4 shows the results of the exploratory analyses of the effects of exposure to dermatologic corticosteroids. Our classification of use according to the daily defined doses during the first trimester and the potency of the corticosteroid did not reveal clear dose-response or potency-response relations.
(Note that the daily defined doses for dermatologic corticosteroids were based on the sizes of the packaging and not on the World Health Organization standards, which do not provide such values for creams and ointments.)
We also compared the use of dermatologic corticosteroids during the first trimester of pregnancy with no use of any corticosteroids during pregnancy and with the use of corticosteroids during other periods of pregnancy. The results of the sensitivity analyses support the results of our main analysis and are summarized in Appendix 1 (available at www .cmaj .ca /cgi/content /full /cmaj .101063 /DC1). Also included in Appendix 1 are the fully adjusted models including all variables identified as potential confounders, singleton children alone and alternative definitions of the main period of exposure.
Interpretation
In a large nationwide cohort of live births, general use of corticosteroids during pregnancy was not significantly associated with an increased risk of orofacial clefts. However, the use of dermatologic corticosteroids was associated with an increased risk of cleft lip with or without cleft palate. In contrast, the use of oral corticosteroids, nasal sprays, inhalants or other topical forms was not associated with an increased risk of clefts.
Systemic corticosteroids have been associated with cleft palate and other adverse events in the fetus in rodents. 1, [25] [26] [27] [28] Topical corticosteroids are assumed to be safer than systemic corticosteroids. However, corticosteroids have been detected in the fetal blood of some animals after topical application, 29 and topical use of diflorasone diacetate has been associated with cleft palate in rabbits. 30 Preparations that contain corticosteroids are among the most frequently prescribed dermatologic treatments. They are commonly used during pregnancy for various skin conditions such as eczema and psoriasis. In humans, topical corticosteroids cross the skin barrier. In a study involving young adults with atopic dermatitis, percutaneous application of 1.0% hydrocortisone cream yielded median serum cortisol levels of 125 nmol/L during the acute phase of the condi- tion and 16 nmol/L during remission. 31 Furthermore, it has been shown that even for a lowpotency corticosteroid such as hydrocortisone, 15.0% of the dose crosses the placenta unmetabolized. 32 These studies suggest fetal serum cortisol levels in the range of 2.4-18.75 nmol/L after the application of 1.0% hydrocortisone cream to the mother's skin.
Many previous epidemiologic studies, though not all, 7 have reported increased risks of orofacial clefts primarily after the use of oral corticosteroids. [3] [4] [5] [6] [8] [9] [10] However, many of the previous studies were limited by a lack of statistical power. The largest study to date, an American case-control study, included 39 instances of orofacial clefts associated with exposure to cortico - Note: CI = confidence interval, OR = odds ratio. *Likelihood ratio test. †Women whose place of residence was not known (1.4%) were excluded from the analysis. ‡Women whose country of origin was not known (0.4%) were excluded from the analysis. §Women for whom smoking status was not known (3.5%) were excluded from the analysis.
steroids, 4 whereas our study included 84 instances associated with exposure during the first trimester. In addition, many of the previous studies determined corticosteroid use through postnatal interviews, which introduced the potential for recall bias.
Studies specifically evaluating topical corticosteroids and orofacial clefts are uncommon. [4] [5] [6] 8, 9 A recent Cochrane review of the safety of topical corticosteroids during pregnancy concluded that the current studies were limited and inconclusive and that cohort studies with very large samples were needed.
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Limitations
We relied on national health registers to find infants with orofacial clefts as defined by ICD-10 codes. The predictive value of the diagnosis of birth defects in the National Hospital Discharge Registry has previously been evaluated as being high (88.0%). 34 We would expect these numbers to be higher for clefts alone, and any misclassification would likely bias our results toward no effect.
Our study did not include abortions. This could introduce bias in a study of drug use during pregnancy and the risk of birth defects, if the birth defect itself increases the risk of planned or spontaneous abortion. It is unlikely that such a bias played a role in a study of birth defects such as isolated orofacial clefts.
We relied on a national prescription drug registry to determine corticosteroid use with the assumption that a filled prescription would lead to use of the drug. However, some divergence with respect to use and timing of use is to be expected, and this divergence would bias our results toward no effect. We were not able to include information on over-the-counter use or hospital use of corticosteroids in this study. Again, we expect that any misclassification would bias our results toward no effect.
Confounding by indication is not obvious in our study; the indications for corticosteroid use are many, and none has been associated with orofacial clefts. That no association was seen between corticosteroid use during late pregnancy and risk of orofacial clefts, despite the apparent increase in Research CMAJ 7 Note: CI = confidence interval, NA = not applicable, OR = odds ratio. *Per 1000 live births. †Odds ratio adjusted for year of birth, maternal place of residence at start of pregnancy, maternal place of origin, smoking status during pregnancy, history of orofacial clefts among offspring and history of any birth defects among offspring. ‡Odds ratio adjusted for year of birth, maternal place of residence at start of pregnancy and history of orofacial clefts among offspring.
risk seen with the use of dermatologic corticosteroids during early pregnancy, also supports the minimal impact of confounding by indication.
The absence of risk associated with corticosteroids taken orally or as inhalants seen in our study should be evaluated in the context of the study's statistical power, which was limited, particularly for oral forms of the drug. However, moderate to high risks can be excluded. For example, for inhalants, we can exclude an increase in the risk of cleft lip with or without cleft palate that is higher than 68%.
The observed association between dermatologic corticosteroids and orofacial clefts in our study may be a result of multiple statistical comparisons. Given that exploratory analyses of the dose-response and potency-response relations between the use of dermatologic corticosteroids and cleft lip with or without cleft palate did not support a causal association, we cannot exclude that the observed results are non-causal random effects. The overall association between dermatologic corticosteroids and orofacial clefts appeared to be carried by hydrocortisone butyrate alone, a corticosteroid on the lower end of the potency scale.
Conclusion
Our results add to the safety information for a class of drugs commonly used during pregnancy. Our study did not show an adverse effect of corticosteroid use during pregnancy on the risk of orofacial clefts. However, the absence of risk associated with cortico steroids taken orally or as inhalants seen in our study does not necessarily show that these products are safe for use during pregnancy.
If the observed association between dermatologic corticosteroids and orofacial clefts seen in our study is causal, it is in contrast to the lack of association seen for corticosteroids taken orally or as inhalants. Since indepth investigation of the pattern of association between orofacial clefts and use of dermatologic corticosteroids during pregnancy indicated that this result did not signify a causal connection, it is likely that this association arose from multiple statistical comparisons. Note: CI = confidence interval, NA = not applicable, OR = odds ratio. *Adjusted for year of birth, maternal place of residence at start of pregnancy, maternal place of origin, smoking status during pregnancy, history of orofacial clefts among offspring and history of any birth defects among offspring. †Adjusted for year of birth, maternal place of residence at start of pregnancy and history of orofacial clefts among offspring. ‡Budesonide, fluocortolone, clobetasone, fluoprednidene, alclometasone, hydrocortisone buteprate, desoximetasone, fluocinolone acetonide, diflucortolone, diflorasone, fluticasone, halcinonide and flumetasone were also used, but no orofacial clefts were seen among the offspring of women taking these medications. §See Appendix 1 for definition of potency and categorization.
